PROF — Profound Medical Corp.

Summary of Profound Medical (PROF) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q4 2025 revenue reached $6 million, a 43% increase from $4.2 million in Q4 2024. This included $2.3 million from recurring revenue and $3.7 million from one-time capital equipment sales.
• Gross Margin: Gross margin was 67%, down from 71% in Q4 2024, attributed to product mix and introductory pricing in new international markets.
• Operating Expenses: Total operating expenses were $11.4 million, slightly up from $11.3 million in Q4 2024.
• Net Loss: The net loss for Q4 2025 was $8.2 million ($0.27 per share), compared to a loss of $4.9 million ($0.20 per share) in the same quarter the previous year.
• Cash Position: As of December 31, 2025, cash reserves stood at $59.7 million.

2. Strategic Updates and Business Highlights

• Clinical Trials: Completion of the CAPTAIN trial, comparing TULSA technology to robotic prostatectomy, is expected to provide significant clinical evidence supporting TULSA's efficacy and quality of life outcomes. Preliminary results will be presented at the European Association of Urology meeting.
• Sales Growth: The company reported 78 TULSA-PRO sites by year-end, with a growing sales pipeline of 110 systems in various stages of negotiation.
• Reimbursement Developments: TULSA procedure reimbursement confirmed for 2026 at urology Level 7, with expectations for private insurance coverage decisions in the latter half of 2026.
• International Expansion: New distribution agreements in Saudi Arabia and Australia are yielding initial sales, with plans to expand further into international markets.

3. Forward Guidance and Outlook

• Revenue Growth: Management anticipates high double-digit to low triple-digit revenue growth in 2026, projecting potential annual revenue of $85 million based on current procedures and installations.
• Cash Flow: The company aims to reduce cash burn and reach cash flow positivity with projected revenues between $80 million and $85 million.
• Utilization Expectations: As more sites adopt TULSA technology and with the introduction of the BPH module, utilization rates are expected to increase significantly in 2026.

4. Challenges and Points of Concern

• Gross Margin Decline: The decrease in gross margin raises concerns about product mix and pricing strategies in new markets.
• Net Loss Increase: The widening net loss indicates ongoing financial challenges as the company invests in growth.
• Utilization Rates: Current average utilization per site is below expectations, with many new installations not yet achieving optimal procedure volumes.
• Competitive Landscape: The company faces competition from established treatment modalities and emerging technologies, necessitating clear differentiation of TULSA's benefits.

5. Notable Q&A Insights

• Reimbursement Dynamics: Management reported that private payers are reimbursing at 1.5x to 2.5x Medicare rates, with over 90% success in overturning prior coverage rejections.
• Utilization Metrics: Average procedures per site are currently low, but management believes 50 procedures per year is a reasonable target, with potential for higher utilization as reimbursement improves.
• Installation Capacity: The company is enhancing logistics and operational capabilities to support increased installations, including the establishment of a U.S. warehouse.
• International Strategy: While the U.S. remains the primary focus, international interest is growing, and the company plans to report on international revenue separately as it becomes more significant.

Overall, Profound Medical is positioned for growth with promising clinical data and expanding market presence, but it must address financial losses and utilization challenges to achieve its ambitious targets.